Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access
- 16 August 2018
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 93 (8) , E188-E190
Abstract
No abstract availableKeywords
Funding Information
- Global Blood Therapeutics, Inc
This publication has 5 references indexed in Scilit:
- Treating sickle cell disease by targeting HbS polymerizationBlood, 2017
- Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization InhibitorBlood, 2016
- GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell diseaseBritish Journal of Haematology, 2016
- GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell DiseaseBlood, 2015
- Sickle-cell diseaseThe Lancet, 2010